Fairvalue-Calculator Fairvalue-Calculator
EN DE

Connect Biopharma Holdings (CNTB) Fair Value & Analysis

Healthcare · US · Market cap $126M

Price$2.09
Fair Value$3.00
Upside+43.5%
Quality95/100
Evidence: Low Range $2.25 – $3.75

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Connect Biopharma Holdings (CNTB) currently trades at $2.09, while our model-based Fair Value estimate is $3.00 — implying the stock looks roughly 43.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Connect Biopharma Holdings (CNTB) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.00 versus a price of $2.09 — about +44% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CNTB?
Our 21-model fair value for Connect Biopharma Holdings is $3.00 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.09.
What is the quality score of CNTB?
Connect Biopharma Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.